Biocept, Inc.
- Jurisdiction
United States - LEI
5493000MP9GU5S88NF42 - ISIN
US09072V6002 (BIOC )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Read full profile
Fundamentals
- Net revenue
-€2.93M - Gross margin
555.8% - EBIT
-€31.89M - EBIT margin
1,088.2% - Net income
-€29.77M - Net margin
1,015.8%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: November 28, 2022 (Q3 2022)